Fermi Matteo, Bassano Edoardo, Villari Domenico, Capriotti Vincenzo, Calvaruso Federico, Bonali Marco, Alicandri-Ciufelli Matteo, Marchioni Daniele, Presutti Livio
Department of Otorhinolaryngology-Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
Department of Specialist, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum, Università di Bologna, Bologna, Italy.
Otolaryngol Head Neck Surg. 2023 Apr;168(4):829-838. doi: 10.1002/ohn.171. Epub 2023 Jan 22.
The aim of the study is to evaluate cholesteatoma's surgical outcomes in patients treated with endoscopic ear surgery (EES) or a combined endoscopic-microscopic approach (cEMA) according to STAM, STAMCO, ChOLE, and EAONO/JOS system (EJS) classifications and staging.
Retrospective study.
Monocentric study in a tertiary referral center.
One-hundred sixty-eight patients who underwent EES or cEMA for cholesteatoma between 2010 and 2018 were classified according to the abovementioned classification and staging. Data on cholesteatoma's recurrence and residual rates were collected. Inferential statistical analysis was performed to evaluate surgical outcomes and the prognostic value of classifications and staging.
The recurrence rate was significantly lower in cholesteatomas classified in EJS stage 1 (2.6%) and STAM stage 1 (0%). A comparison of the different stages of the disease showed a significantly lower recurrence only for stage 1 versus the superior stages of both classifications. Involvement of mastoid bone was associated with a higher risk of recurrence (odds ratio [OR]: 4.12; p = .031). Attical involvement was associated with a higher risk of residual cholesteatoma (OR: 1.165; p = .046).
EES or cEMA represents an effective treatment for middle ear cholesteatoma. The STAM classification and the EJS have shown a prognostic value, with STAM 1 and EAONO-JOS 1 stages associated with a better prognosis. Mastoid involvement represents a risk factor for recurrence. Attic localization is associated with residual disease. Localization at difficult access sites did not implicate a higher risk for recurrence or residual. ChOLE classification, Ossicular chain status, and complication status did not provide prognostic information regarding recurrence or residual cholesteatoma.
本研究旨在根据STAM、STAMCO、ChOLE和EAONO/JOS系统(EJS)分类及分期,评估接受耳内镜手术(EES)或内镜-显微镜联合入路(cEMA)治疗的胆脂瘤患者的手术效果。
回顾性研究。
在一家三级转诊中心进行的单中心研究。
对2010年至2018年间因胆脂瘤接受EES或cEMA治疗的168例患者,根据上述分类及分期进行分类。收集胆脂瘤复发率和残留率的数据。进行推断性统计分析以评估手术效果以及分类和分期的预后价值。
EJS 1期(2.6%)和STAM 1期(0%)分类的胆脂瘤复发率显著较低。对疾病不同阶段的比较显示,仅1期与两种分类的更高阶段相比,复发率显著更低。乳突骨受累与更高的复发风险相关(优势比[OR]:4.12;p = 0.031)。上鼓室受累与残留胆脂瘤的更高风险相关(OR:1.165;p = 0.046)。
EES或cEMA是治疗中耳胆脂瘤的有效方法。STAM分类和EJS显示出预后价值,STAM 1期和EAONO-JOS 1期预后较好。乳突受累是复发的危险因素。上鼓室定位与残留疾病相关。位于难以到达部位的病变并未暗示更高的复发或残留风险。ChOLE分类、听骨链状态和并发症状态未提供关于胆脂瘤复发或残留的预后信息。